Politics / Law

Messages from the EU's Survey on R&D

22.08.2011

Brussels – As this ‘Heard in Brussels’ is being written, the ‘Heard’ element of my column is fairly ironic, as all you can hear in Brussels in August is the sound of tumbleweeds blowing down empty streets as politicians and their minions head off to their châteaux in the south …
Now is the time of year to get all that work done that has piled up in your in-box, and this August is no different. We have Europe’s 2010 Survey on R&D Investment Business Trends just published, and in the midst of an epic global recession, it delivers good reading and key warning points for biotechnology spending in Europe. R&D funding didn't collapse as much as feared in Europe, and cautious increases are forecast for 2011. BUT, the percentage of spending is miniscule compared to the rest of the world. Many new young highly-innovative markets are being fuelled by greater economic growth than in Europe. At the same time, the established giants are having to reorder themselves and squeeze maximum revenue from reduced spend.

Still a long way to go

The perennial issue of access to the right skills has been an important positive aspect for Europe. We have brilliant people in science and in business, and as investors and companies over the years have learned, it is the people that create success – the technology is secondary. Europe needs to continue growing great business managers for science, and get ruthless with those that stifle a technology with their inability to develop it as a business or product. A great technology is not chained to its inventor or the inventing organisation, especially if it's come from publicly-funded research. It belongs to the taxpayer. The issue of IPR was negative for EVERYBODY in the R&D survey, and this is ridiculous – it is so fixable within Europe, and a perfect example of how fragmented the EU chooses to make itself. There is no excuse whatsoever for the continued delay in a European patent. It remains a serious barrier to technology-driven economic growth.
A big ‘well done’ for Germany as well, the only European country to feature in the top three for R&D investment outside a company’s home country. France and the UK in particular should be wondering why they don’t feature more strongly. If Europe is to deliver on its innovation potential, it should be much more attractive to R&D investment from abroad. Finally and very positively, the greatest demand for collaboration was with other companies. B2B research partnerships have featured strongly in the last 12 months for the European Biotechnology Network, and the rewards are being felt in the shape of strong results across all biotech sectors.
Time to return to roaming the empty streets of Brussels. But in just a few more weeks they'll have filled again – and I will have cleared my in-box.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/messages-from-the-eus-survey-on-rd.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR221.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK49.8%
  • Allergy Therapeutics (UK)20.00 GBP33.3%

FLOP

  • HYBRIGENICS (F)1.68 EUR-28.5%
  • METABOLIC EXPLORER (F)2.88 EUR-21.3%
  • VITA 34 (D)4.16 EUR-20.6%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR290.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-93.0%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-71.0%

No liability assumed, Date: 01.08.2014


Current issue

All issues

Product of the week

Products